登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07647029,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Nadir platelet count < 50×10⁹/L in the previous antitumor treatment cycle;
入选标准第 6 条
Nadir platelet count ≥ 50×10⁹/L but < 75×10⁹/L in the previous antitumor treatment cycle, accompanied by **high risk factors for bleeding***;
入选标准第 7 条
Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose, not be breastfeeding, and agree to use effective contraception during the study and for 7 days after the last dose of study drug.
入选标准第 14 条
ECOG performance status 0-2;
入选标准第 4 条
Platelet count ≥ 100×10⁹/L at enrollment;
入选标准第 8 条
Bone marrow: ANC ≥ 1.5×10⁹/L; hemoglobin ≥ 8 g/dL;
入选标准第 11 条
Hepatic and renal function: total bilirubin ≤ 1.5 × ULN; ALT, AST ≤ 2.5 × ULN (or ≤ 5 × ULN in the presence of liver metastasis); serum creatinine ≤ 1.5 × ULN or creatinine clearance > 60 mL/min (Cockcroft-Gault formula);
入选标准第 12 条
Coagulation: activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN;
入选标准第 13 条
Pregnant or breastfeeding women, or female patients of childbearing potential not using effective contraception;
排除标准第 5 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07647029,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥ 18 years; Patients with histopathologically confirmed breast cancer; Receiving or expected to receive chemotherapy-based antitumor therapy with a cycle length of ≥21 days, and anticipated to receive ≥2 cycles of therapy; ECOG performance status 0-2; Platelet count meeting **one** of the following criteria: Nadir platelet count < 50×10⁹/L in the previous antitumor treatment cycle; Nadir platelet count ≥ 50×10⁹/L but < 75×10⁹/L in the previous antitumor treatment cycle, accompanied by **high risk factors for bleeding***; Platelet count ≥ 100×10⁹/L at enrollment; Patients with breast cancer plus other malignancies are allowed, provided that the treatment plan is primarily for breast cancer; Adequate organ function: Bone marrow: ANC ≥ 1.5×10⁹/L; hemoglobin ≥ 8 g/dL; Hepatic and renal function: total bilirubin ≤ 1.5 × ULN; ALT, AST ≤ 2.5 × ULN (or ≤ 5 × ULN in the presence of liver metastasis); serum creatinine ≤ 1.5 × ULN or creatinine clearance > 60 mL/min (Cockcroft-Gault formula); Coagulation: activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN; Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose, not be breastfeeding, and agree to use effective contraception during the study and for 7 days after the last dose of study drug. Life expectancy ≥ 3 months; Voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to comply with follow-up procedures. High risk factors for bleeding History of bleeding; prior treatment with platinum agents, gemcitabine, cytarabine, anthracyclines, PARP inhibitors (e.g., niraparib), etc.; combination of targeted agents and chemotherapeutic agents known to increase the risk of thrombocytopenia; history of radiotherapy or ongoing radiotherapy, especially to long bones and flat bones (e.g., pelvis, sternum).排除标准:Exclusion Criteria:
Presence of hematological disorders, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative neoplasms, multiple myeloma, and myelodysplastic syndromes; Uncontrolled active infection; History of arterial or venous thrombosis; Patients with bleeding tendency, or evidence of inherited bleeding diathesis or coagulation disorders; Pregnant or breastfeeding women, or female patients of childbearing potential not using effective contraception; Participation in another clinical trial of thrombopoietic agents within 4 weeks prior to enrollment; Presence of uncontrolled neurological or psychiatric disorders, poor compliance, or inability to cooperate and report treatment-related reactions; Bone marrow involvement; Administration of rhTPO or rhIL-11 within 7 days prior to enrollment; Hypersensitivity to the study drug(s).
引自 ClinicalTrials.gov, NCT07647029, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07647029,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。